RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8.

RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8.

July 2, 2025

In a recent update, UBS Financial Services has revised its price target for RAPT Therapeutics (NASDAQ: RAPT) from $8 to $9. This adjustment reflects the investment bank's analysis of the company's financial performance and strategic developments. The updated price target is based on a neutral rating, indicating a balanced view of RAPT's prospects.

Financial Performance

RAPT Therapeutics reported its first quarter 2025 financial results, showing a significant improvement in net loss to $17.2 million compared to $30.5 million in Q1 2024 [1]. The company's research and development expenses decreased to $12.0 million from $24.8 million year-over-year, while general and administrative expenses slightly decreased to $7.2 million from $7.7 million. Despite the net loss, RAPT maintained a strong cash position of $179.3 million as of March 31, 2025.

Clinical Progress

The company's CEO, Brian Wong, highlighted progress with RPT904, a food allergy treatment candidate, with plans to initiate a Phase 2b trial in H2 2025. The company is also anticipating clinical data for RPT904 in chronic spontaneous urticaria (CSU) from their partner Jemincare later this year [1].

Strategic Appointments

RAPT has appointed Dr. Jessica Savage as Vice President of Clinical Development to lead the development of RPT904. Dr. Savage brings significant expertise in food allergy research and clinical development, having previously held leadership positions at Harvard Medical School, Johns Hopkins University, and Alexion [2].

Investor Conferences

RAPT Therapeutics has announced its participation in several investor conferences in 2025, including the Goldman Sachs 46th Annual Global Healthcare Conference and the UBS Spring Biotech Conference. These events provide opportunities for the company to present its progress and engage with investors [3].

UBS Analysis

UBS analysts have noted the company's strong pipeline, particularly the potential of RPT904, and the strategic appointment of Dr. Savage. The investment bank expects the company's clinical trials and partnerships to drive growth and improve financial performance.

References

[1] https://www.stocktitan.net/news/RAPT/
[2] https://www.stocktitan.net/news/RAPT/2025/03/07/108437/
[3] https://www.stocktitan.net/news/RAPT/2025/06/04/108437/